Literature DB >> 33361384

Phenotypic Mapping of Pathologic Cross-Talk between Glioblastoma and Innate Immune Cells by Synthetic Genetic Tracing.

Matthias Jürgen Schmitt1, Carlos Company1, Yuliia Dramaretska1, Iros Barozzi2, Andreas Göhrig1, Sonia Kertalli1, Melanie Großmann1, Heike Naumann1, Maria Pilar Sanchez-Bailon1, Danielle Hulsman3, Rainer Glass4, Massimo Squatrito5, Michela Serresi1, Gaetano Gargiulo6.   

Abstract

Glioblastoma is a lethal brain tumor that exhibits heterogeneity and resistance to therapy. Our understanding of tumor homeostasis is limited by a lack of genetic tools to selectively identify tumor states and fate transitions. Here, we use glioblastoma subtype signatures to construct synthetic genetic tracing cassettes and investigate tumor heterogeneity at cellular and molecular levels, in vitro and in vivo. Through synthetic locus control regions, we demonstrate that proneural glioblastoma is a hardwired identity, whereas mesenchymal glioblastoma is an adaptive and metastable cell state driven by proinflammatory and differentiation cues and DNA damage, but not hypoxia. Importantly, we discovered that innate immune cells divert glioblastoma cells to a proneural-to-mesenchymal transition that confers therapeutic resistance. Our synthetic genetic tracing methodology is simple, scalable, and widely applicable to study homeostasis in development and diseases. In glioblastoma, the method causally links distinct (micro)environmental, genetic, and pharmacologic perturbations and mesenchymal commitment. SIGNIFICANCE: Glioblastoma is heterogeneous and incurable. Here, we designed synthetic reporters to reflect the transcriptional output of tumor cell states and signaling pathways' activity. This method is generally applicable to study homeostasis in normal tissues and diseases. In glioblastoma, synthetic genetic tracing causally connects cellular and molecular heterogeneity to therapeutic responses.This article is highlighted in the In This Issue feature, p. 521. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33361384      PMCID: PMC7611210          DOI: 10.1158/2159-8290.CD-20-0219

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  59 in total

1.  Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma.

Authors:  Krishna P L Bhat; Veerakumar Balasubramaniyan; Brian Vaillant; Ravesanker Ezhilarasan; Howard Colman; Erik P Sulman; Kenneth Aldape; Karlijn Hummelink; Faith Hollingsworth; Khalida Wani; Lindsey Heathcock; Johanna D James; Lindsey D Goodman; Siobhan Conroy; Lihong Long; Nina Lelic; Suzhen Wang; Joy Gumin; Divya Raj; Yoshinori Kodama; Aditya Raghunathan; Adriana Olar; Kaushal Joshi; Christopher E Pelloski; Amy Heimberger; Se Hoon Kim; Daniel P Cahill; Ganesh Rao; Wilfred F A Den Dunnen; Hendrikus W G M Boddeke; Heidi S Phillips; Ichiro Nakano; Frederick F Lang
Journal:  Cancer Cell       Date:  2013-08-29       Impact factor: 31.743

2.  Erratum: An in vivo model of functional and vascularized human brain organoids.

Authors:  Abed AlFatah Mansour; J Tiago Gonçalves; Cooper W Bloyd; Hao Li; Sarah Fernandes; Daphne Quang; Stephen Johnston; Sarah L Parylak; Xin Jin; Fred H Gage
Journal:  Nat Biotechnol       Date:  2018-08-06       Impact factor: 54.908

3.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.

Authors:  Shideng Bao; Qiulian Wu; Roger E McLendon; Yueling Hao; Qing Shi; Anita B Hjelmeland; Mark W Dewhirst; Darell D Bigner; Jeremy N Rich
Journal:  Nature       Date:  2006-10-18       Impact factor: 49.962

4.  Wnt5a Drives an Invasive Phenotype in Human Glioblastoma Stem-like Cells.

Authors:  Elena Binda; Alberto Visioli; Fabrizio Giani; Nadia Trivieri; Orazio Palumbo; Silvia Restelli; Fabio Dezi; Tommaso Mazza; Caterina Fusilli; Federico Legnani; Massimo Carella; Francesco Di Meco; Rohit Duggal; Angelo L Vescovi
Journal:  Cancer Res       Date:  2016-12-23       Impact factor: 12.701

5.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.

Authors:  Heidi S Phillips; Samir Kharbanda; Ruihuan Chen; William F Forrest; Robert H Soriano; Thomas D Wu; Anjan Misra; Janice M Nigro; Howard Colman; Liliana Soroceanu; P Mickey Williams; Zora Modrusan; Burt G Feuerstein; Ken Aldape
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

6.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

7.  Position-independent, high-level expression of the human beta-globin gene in transgenic mice.

Authors:  F Grosveld; G B van Assendelft; D R Greaves; G Kollias
Journal:  Cell       Date:  1987-12-24       Impact factor: 41.582

8.  Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma.

Authors:  Sangeeta Goswami; Thomas Walle; Andrew E Cornish; Sreyashi Basu; Swetha Anandhan; Irina Fernandez; Luis Vence; Jorge Blando; Hao Zhao; Shalini Singh Yadav; Martina Ott; Ling Y Kong; Amy B Heimberger; John de Groot; Boris Sepesi; Michael Overman; Scott Kopetz; James P Allison; Dana Pe'er; Padmanee Sharma
Journal:  Nat Med       Date:  2019-12-23       Impact factor: 53.440

9.  A restricted cell population propagates glioblastoma growth after chemotherapy.

Authors:  Jian Chen; Yanjiao Li; Tzong-Shiue Yu; Renée M McKay; Dennis K Burns; Steven G Kernie; Luis F Parada
Journal:  Nature       Date:  2012-08-23       Impact factor: 49.962

10.  The transcriptional network for mesenchymal transformation of brain tumours.

Authors:  Maria Stella Carro; Wei Keat Lim; Mariano Javier Alvarez; Robert J Bollo; Xudong Zhao; Evan Y Snyder; Erik P Sulman; Sandrine L Anne; Fiona Doetsch; Howard Colman; Anna Lasorella; Ken Aldape; Andrea Califano; Antonio Iavarone
Journal:  Nature       Date:  2009-12-23       Impact factor: 49.962

View more
  12 in total

Review 1.  Engineering in vitro immune-competent tissue models for testing and evaluation of therapeutics.

Authors:  Jennifer H Hammel; Jonathan M Zatorski; Sophie R Cook; Rebecca R Pompano; Jennifer M Munson
Journal:  Adv Drug Deliv Rev       Date:  2022-01-11       Impact factor: 15.470

2.  Elucidating the diversity of malignant mesenchymal states in glioblastoma by integrative analysis.

Authors:  Rony Chanoch-Myers; Adi Wider; Mario L Suva; Itay Tirosh
Journal:  Genome Med       Date:  2022-09-19       Impact factor: 15.266

Review 3.  Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma.

Authors:  Lizhi Pang; Fatima Khan; Amy B Heimberger; Peiwen Chen
Journal:  Trends Cancer       Date:  2022-05-24

Review 4.  Brain cancer stem cells: resilience through adaptive plasticity and hierarchical heterogeneity.

Authors:  Ryan C Gimple; Kailin Yang; Matthew E Halbert; Sameer Agnihotri; Jeremy N Rich
Journal:  Nat Rev Cancer       Date:  2022-06-16       Impact factor: 69.800

5.  Chemerin enhances mesenchymal features of glioblastoma by establishing autocrine and paracrine networks in a CMKLR1-dependent manner.

Authors:  Jianqi Wu; Shuai Shen; Tianqi Liu; Xiufang Ren; Chen Zhu; Qingyu Liang; Xiao Cui; Ling Chen; Peng Cheng; Wen Cheng; Anhua Wu
Journal:  Oncogene       Date:  2022-04-22       Impact factor: 8.756

Review 6.  Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence.

Authors:  Daniel Kreatsoulas; Chelsea Bolyard; Bill X Wu; Hakan Cam; Pierre Giglio; Zihai Li
Journal:  J Hematol Oncol       Date:  2022-06-11       Impact factor: 23.168

7.  Tracing the origins of glioblastoma by investigating the role of gliogenic and related neurogenic genes/signaling pathways in GBM development: a systematic review.

Authors:  Ovais Shafi; Ghazia Siddiqui
Journal:  World J Surg Oncol       Date:  2022-05-10       Impact factor: 3.253

Review 8.  Neurofibromatosis Type 1 Gene Alterations Define Specific Features of a Subset of Glioblastomas.

Authors:  Maximilian Scheer; Sandra Leisz; Eberhard Sorge; Olha Storozhuk; Julian Prell; Ivy Ho; Anja Harder
Journal:  Int J Mol Sci       Date:  2021-12-29       Impact factor: 5.923

9.  Functional antagonism of chromatin modulators regulates epithelial-mesenchymal transition.

Authors:  Michela Serresi; Sonia Kertalli; Lifei Li; Matthias Jürgen Schmitt; Yuliia Dramaretska; Jikke Wierikx; Danielle Hulsman; Gaetano Gargiulo
Journal:  Sci Adv       Date:  2021-02-24       Impact factor: 14.136

Review 10.  The Eclectic Nature of Glioma-Infiltrating Macrophages and Microglia.

Authors:  Víctor A Arrieta; Hinda Najem; Edgar Petrosyan; Catalina Lee-Chang; Peiwen Chen; Adam M Sonabend; Amy B Heimberger
Journal:  Int J Mol Sci       Date:  2021-12-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.